Specifically, the BRAF inhibitor dabrafenib (Tafinlar, Novartis Pharmaceuticals Corp) and MEK inhibitor trametinib (Mekinist, Novartis Pharmaceuticals Corp), which were shown to be efficacious in patients with metastatic BRAF-mutant melanomas, were brought into the adjuvant setting. This evidence concerns the gene MAP2K7 and melanoma.